Matthias Cavassini

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


380 publications

Sous presse | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ...
 
Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients.
Abela I.A., Scherrer A.U., Böni J., Yerly S., Klimkait T., Perreau M., Hirsch H.H., Furrer H., Calmy A., Schmid P. et al. Clinical infectious diseases. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_5CD4824E50AC]
 
Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.
Barcelo C., Aouri M., Courlet P., Guidi M., Braun D.L., Günthard H.F., Piso R.J., Cavassini M., Buclin T., Decosterd L.A. et al. The Journal of antimicrobial chemotherapy. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_525CE7DE74FD]
 
Impact of screening and ART on anal cancer incidence in HIV-positive men who have sex with men: mathematical modeling study.
Blaser N., Bertisch B., Kouyos R.D., Calmy A., Bucher H.C., Cavassini M., Estill J., Keiser O., Egger M., Swiss HIV Cohort Study AIDS (London, England). Peer-reviewed.
[DOI] [Pmid] [serval:BIB_F647BA53F368]
 
Viral diversity from next-generation sequencing of HIV-1 samples provides precise estimates of infection recency and time since infection.
Carlisle L.A., Turk T., Kusejko K., Metzner K.J., Leemann C., Schenkel C., Bachmann N., Posada S., Beerenwinkel N., Böni J. et al. The Journal of infectious diseases. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_19B3C834E3FA]
 
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.
Courlet P., Decosterd L.A., Brown J.A., Alves Saldanha S., Marzolini C., Cavassini M., Stoeckle M., Csajka C., Labhardt N.D., Calmy A. The Journal of antimicrobial chemotherapy. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_5082024839D9]
 
Escitalopram population pharmacokinetics in people living with HIV and in the psychiatric population: drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al. British journal of clinical pharmacology. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_F5C6318349C9]
 
Contribution of genetic background and clinical D:A:D risk score to chronic kidney disease in Swiss HIV-positive persons with normal baseline estimated glomerular filtration rate.
Dietrich L.G., Barceló C., Thorball C.W., Ryom L., Burkhalter F., Hasse B., Furrer H., Weisser M., Steffen A., Bernasconi E. et al. Clinical infectious diseases. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_CEFAD592E5CD]
 
A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, non-communicable and opportunistic diseases.
Kusejko K., Bachmann N., Chaudron S.E., Nguyen H., Braun D.L., Hampel B., Battegay M., Bernasconi E., Calmy A., Cavassini M. et al. The Journal of infectious diseases. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_BB6E66056535]
 
HIV transmission chains exhibit greater HLA-B homogeneity than randomly expected.
Nguyen H., Thorball C.W., Fellay J., Böni J., Yerly S., Perreau M., Klimkait T., Kusjeko K., Bachmann N., Chaudron S.E. et al. Journal of acquired immune deficiency syndromes. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_6E0F5A3E41D4]
 
Changing trends in international versus domestic HCV transmission in HIV-positive MSM: A perspective for the DAA scale-up era.
Salazar-Vizcaya L., Kouyos R.D., Metzner K.J., Caraballo Cortes K., Böni J., Shah C., Fehr J., Braun D.L., Bernasconi E., Mbunkah H.A. et al. The Journal of infectious diseases. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_DB771CDF18E0]
 
The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.
Young J., Scherrer A.U., Calmy A., Tarr P.E., Bernasconi E., Cavassini M., Hachfeld A., Vernazza P., Günthard H.F., Bucher H.C. et al. Antiviral therapy. Peer-reviewed.
[DOI] [Pmid] [serval:BIB_EE3F2AF63928]
Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy.
Gras L., May M., Ryder L.P., Trickey A., Helleberg M., Obel N., Thiebaut R., Guest J., Gill J., Crane H. et al., 2019/03/01. Journal of acquired immune deficiency syndromes, 80 (3) pp. 292-300. Peer-reviewed.
 
Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study.
Leon-Reyes S., Schäfer J., Früh M., Schwenkglenks M., Reich O., Schmidlin K., Staehelin C., Battegay M., Cavassini M., Hasse B. et al., 2019/02/15. Clinical infectious diseases, 68 (5) pp. 827-833. Peer-reviewed.
 
Nouveautés dans le dépistage, la prévention et la prise en charge du VIH en 2018 [Diagnosis, prevention and treatment of HIV : what's new in 2018 ?]
D'Incau S., Viala B., Ciuffi A., Cavassini M., Calmy A., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 107-112. Peer-reviewed.
 
Non-targeted HIV testing in the emergency department: not just how but where.
Tan R., Hugli O., Cavassini M., Darling K., 2018/12. Expert review of anti-infective therapy, 16 (12) pp. 893-905. Peer-reviewed.
 
Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma.
Bibert S., Wójtowicz A., Taffé P., Tarr P.E., Bernasconi E., Furrer H., Günthard H.F., Hoffmann M., Kaiser L., Osthoff M. et al., 2018/11/28. AIDS, 32 (18) pp. 2759-2765. Peer-reviewed.
 
Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland.
Kusejko K., Marzel A., Hampel B., Bachmann N., Nguyen H., Fehr J., Braun D.L., Battegay M., Bernasconi E., Calmy A. et al., 2018/11. HIV medicine, 19 (10) pp. 688-697. Peer-reviewed.
CD32<sup>+</sup> and PD-1<sup>+</sup> Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals.
Noto A., Procopio F.A., Banga R., Suffiotti M., Corpataux J.M., Cavassini M., Riva A., Fenwick C., Gottardo R., Perreau M. et al., 2018/10/15. Journal of virology, 92 (20). Peer-reviewed.
Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015.
Lazzarino T., Martenet S., Mamin R., Du Pasquier R.A., Peters S., Perreau M., Muller O., Hugli O., Cavassini M., Darling KEA, 2018/10/03. BMJ open, 8 (10) pp. e021203. Peer-reviewed.
 
Content analysis of antiretroviral adherence enhancing interview reports.
Kamal S., Nulty P., Bugnon O., Cavassini M., Schneider M.P., 2018/09. Patient education and counseling, 101 (9) pp. 1676-1682. Peer-reviewed.
 
Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.
Kouyos R.D., Rusert P., Kadelka C., Huber M., Marzel A., Ebner H., Schanz M., Liechti T., Friedrich N., Braun D.L. et al., 2018/09. Nature, 561 (7723) pp. 406-410. Peer-reviewed.
Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study.
Salazar-Vizcaya L., Wandeler G., Fehr J., Braun D., Cavassini M., Stoeckle M., Bernasconi E., Hoffmann M., Rougemont M., Béguelin C. et al., 2018/07. Open forum infectious diseases, 5 (7) pp. ofy154. Peer-reviewed.
Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study.
Kusejko K., Kadelka C., Marzel A., Battegay M., Bernasconi E., Calmy A., Cavassini M., Hoffmann M., Böni J., Yerly S. et al., 2018/07. Virus evolution, 4 (2) pp. vey024. Peer-reviewed.
 
Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men.
Aebi-Popp K., Wandeler G., Salazar-Vizcaya L., Metzner K., Stöckle M., Cavassini M., Hoffmann M., Lüthi A., Suter F., Bernasconi E. et al., 2018/07. HIV medicine, 19 (6) pp. 420-425. Peer-reviewed.
Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ :  CD8+ ratio.
Hughes R.A., May M.T., Tilling K., Taylor N., Wittkop L., Reiss P., Gill J., Schommers P., Costagliola D., Guest J.L. et al., 2018/06/19. AIDS, 32 (10) pp. 1361-1367. Peer-reviewed.
Missed opportunities for HIV testing among patients newly presenting for HIV care at a Swiss university hospital: a retrospective analysis.
Lhopitallier L., Moulin E., Hugli O., Cavassini M., Darling KEA, 2018/06/12. BMJ open, 8 (6) pp. e019806. Peer-reviewed.
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.
Kadelka C., Liechti T., Ebner H., Schanz M., Rusert P., Friedrich N., Stiegeler E., Braun D.L., Huber M., Scherrer A.U. et al., 2018/06/04. The Journal of experimental medicine, 215 (6) pp. 1589-1608. Peer-reviewed.
 
Long-term trends in CD4 cell counts, CD8 cell counts, and the CD4: CD8 ratio: ART Cohort Collaboration (ART-CC) Study.
Hughes R.A., May M.T., Tilling K., Taylor N., Wittkop L., Reiss P., Gill J., Schommers P., Costagliola D., Guest J.L. et al., 2018/05/03. AIDS pp. 1361-1367. Peer-reviewed.
 
Le voyageur face au VIH et le voyageur vivant avec le VIH [Travelers' exposure to HIV and HIV-infected travelers]
Boillat-Blanco N., Cavassini M., Genton B., 2018/05/02. Revue medicale suisse, 14 (605) pp. 918-921. Peer-reviewed.
The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis.
Marzel A., Kusejko K., Weber R., Bruggmann P., Rauch A., Roth J.A., Bernasconi E., Calmy A., Cavassini M., Hoffmann M. et al., 2018/05. Open forum infectious diseases, 5 (5) pp. ofy078. Peer-reviewed.
Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-Infected Cells.
Golumbeanu M., Cristinelli S., Rato S., Munoz M., Cavassini M., Beerenwinkel N., Ciuffi A., 2018/04/24. Cell reports, 23 (4) pp. 942-950. Peer-reviewed.
 
Are privacy-enhancing technologies for genomic data ready for the clinic? A survey of medical experts of the Swiss HIV Cohort Study.
Raisaro J.L., McLaren P.J., Fellay J., Cavassini M., Klersy C., Hubaux J.P., Swiss HIV Cohort Study, 2018/03. Journal of biomedical informatics, 79 pp. 1-6. Peer-reviewed.
Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C., Suter A., Bernasconi E., Fehr J., Kovari H., Bucher H.C., Stoeckle M., Cavassini M., Rougemont M., Schmid P. et al., 2018/03. Liver international, 38 (3) pp. 424-431. Peer-reviewed.
 
Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord, 2018/02/01. Clinical infectious diseases, 66 (4) pp. 594-603. Peer-reviewed.
 
Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?
Mocroft A., Laut K., Reiss P., Gatell J., Ormaasen V., Cavassini M., Hadziosmanovic V., Mansinho K., Pradier C., Vasylyev M. et al., 2018/01/14. AIDS, 32 (2) pp. 205-215. Peer-reviewed.
 
A prospective multicentre study of healthcare provider preference in rapid HIV testing kits: Determine versus INSTI.
Amyai N., Darling K., D'Acremont V., Castro E., Ebert S., Diserens M.M., Perdrix J., Fossati A.H., Bodenmann P., Cavassini M., 2018/01. International journal of STD & AIDS, 29 (1) pp. 51-56. Peer-reviewed.
 
Blood CXCR3 (+) CD4 T Cells Are Enriched in Inducible Replication Competent HIV in Aviremic Antiretroviral Therapy-Treated Individuals.
Banga R., Procopio F.A., Ruggiero A., Noto A., Ohmiti K., Cavassini M., Corpataux J.M., Paxton W.A., Pollakis G., Perreau M., 2018. Frontiers in immunology, 9 p. 144. Peer-reviewed.
Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity.
Bertels F., Marzel A., Leventhal G., Mitov V., Fellay J., Günthard H.F., Böni J., Yerly S., Klimkait T., Aubert V. et al., 2018/01/01. Molecular biology and evolution, 35 (1) pp. 27-37. Peer-reviewed.
 
HIV and Aging - Perhaps Not as Dramatic as We Feared?
Engel T., Raffenberg M., Marzolini C., Cavassini M., Kovari H., Hasse B., Tarr P.E., 2018. Gerontology, 64 (5) pp. 446-456. Peer-reviewed.
 
HIV-infected patients' beliefs about their chronic co-treatments in comparison with their combined antiretroviral therapy.
Kamal S., Bugnon O., Cavassini M., Schneider M.P., 2018/01. HIV medicine, 19 (1) pp. 49-58. Peer-reviewed.
Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation.
Pettit A.C., Giganti M.J., Ingle S.M., May M.T., Shepherd B.E., Gill M.J., Fätkenheuer G., Abgrall S., Saag M.S., Del Amo J. et al., 2018/01. Journal of the International AIDS Society, 21 (1) pp. NA. Peer-reviewed.
Molecular characterization of Treponema pallidum subsp. pallidum in Switzerland and France with a new multilocus sequence typing scheme.
Grillová L., Bawa T., Mikalová L., Gayet-Ageron A., Nieselt K., Strouhal M., Sednaoui P., Ferry T., Cavassini M., Lautenschlager S. et al., 2018. PloS one, 13 (7) pp. e0200773. Peer-reviewed.
Targeted versus non-targeted HIV testing offered via electronic questionnaire in a Swiss emergency department: A randomized controlled study.
Gillet C., Darling KEA, Senn N., Cavassini M., Hugli O., 2018. PloS one, 13 (3) pp. e0190767. Peer-reviewed.
 
Travailleuses du sexe et accès aux soins
Gloor E., Mestre-Augustoni G., Ansemert-Pago A., Vaucher P., Durieux-Paillard S., Bodenmann P., Cavassini M., 2018. pp. 163-172 dans Bodemann Patrick (eds.) Vulnérabilités, équité et santé chap. 2.4, RMS Editions.
Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.
Perrotta G., Bonnier G., Meskaldji D.E., Romascano D., Aydarkhanov R., Daducci A., Simioni S., Cavassini M., Metral M., Lazeyras F. et al., 2017/12. Annals of clinical and translational neurology, 4 (12) pp. 915-920. Peer-reviewed.
 
Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships.
Marzel A., Shilaih M., Turk T., Campbell N.K., Yang W.L., Böni J., Yerly S., Klimkait T., Aubert V., Furrer H. et al., 2017/10. HIV medicine, 18 (9) pp. 667-676. Peer-reviewed.
CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).
Trickey A., May M.T., Schommers P., Tate J., Ingle S.M., Guest J.L., Gill M.J., Zangerle R., Saag M., Reiss P. et al., 2017/09/15. Clinical infectious diseases, 65 (6) pp. 959-966. Peer-reviewed.
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis.
Turk T., Bachmann N., Kadelka C., Böni J., Yerly S., Aubert V., Klimkait T., Battegay M., Bernasconi E., Calmy A. et al., 2017/09/12. eLife, 6 p. 1. Peer-reviewed.
 
Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study.
Gebreselassie H.M., Kraus D., Fux C.A., Haubitz S., Scherrer A., Hatz C., Veit O., Stoeckle M., Fehr J., de Lucia S. et al., 2017/09. HIV medicine, 18 (8) pp. 564-572. Peer-reviewed.
Adverse events of raltegravir and dolutegravir.
Elzi L., Erb S., Furrer H., Cavassini M., Calmy A., Vernazza P., Günthard H., Bernasconi E., Battegay M., Swiss HIV Cohort Study Group, 2017/08/24. AIDS, 31 (13) pp. 1853-1858. Peer-reviewed.
 
Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSM.
Blaser N., Bertisch B., Kouyos R.D., Calmy A., Bucher H.C., Cavassini M., Estill J., Keiser O., Egger M., Swiss HIV Cohort Study, 2017/08/24. AIDS, 31 (13) pp. 1859-1866. Peer-reviewed.
 
High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study.
Schäfer J., Young J., Calmy A., Nicca D., Hasse B., Brun Del Re C., Cavassini M., Bernasconi E., Schmidt-Trucksäss A., Bucher H.C. et al., 2017/08. AIDS care, 29 (8) pp. 1056-1061. Peer-reviewed.
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.
Antiretroviral Therapy Cohort Collaboration, 2017/08. The lancet. HIV, 4 (8) pp. e349-e356. Peer-reviewed.
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Sculier D., Gayet-Ageron A., Battegay M., Cavassini M., Fehr J., Hirzel C., Schmid P., Bernasconi E., Calmy A., Swiss HIV Cohort Study, 2017/07/06. BMC infectious diseases, 17 (1) p. 476. Peer-reviewed.
 
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.
Béguelin C., Friolet N., Moradpour D., Sahli R., Suter-Riniker F., Lüthi A., Cavassini M., Günthard H.F., Battegay M., Bernasconi E. et al., 2017/05/01. Clinical infectious diseases, 64 (9) pp. 1275-1278. Peer-reviewed.
 
Evaluation de la plateforme Neuro-VIH d’un hôpital universitaire par les patients et les médecins traitants [Evaluation of an outpatient multidisciplinary Neuro-HIV clinic by the patients and referring doctors]
Vallotton K., Métral M., Chocron O., Meuli R., Alves D., Du Pasquier R., Cavassini M., 2017/04/12. Revue medicale suisse, 13 (558) pp. 782-786. Peer-reviewed.
 
Guidelines : fausse route ou voie dorée ?
Huttner B., Cavassini M., 2017/04/12. Revue medicale suisse, 13 (558) pp. 779-780. Peer-reviewed.
 
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M., Barcelo C., Guidi M., Rotger M., Cavassini M., Hizrel C., Buclin T., Decosterd L.A., Csajka C., Swiss HIV Cohort Study, 2017/04. Antimicrobial agents and chemotherapy, 61 (1) p. 10. Peer-reviewed.
 
Human papillomavirus antibody response following HAART initiation among MSM.
Combes J.D., Clifford G.M., Egger M., Cavassini M., Hirsch H.H., Hauser C., Calmy A., Schmid P., Bernasconi E., Günthard H.F. et al., 2017/02/20. AIDS, 31 (4) pp. 561-569. Peer-reviewed.
 
Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study.
Kovari H., Rauch A., Kouyos R., Rougemont M., Cavassini M., Schmid P., Stöckle M., Bernasconi E., Weber R., Ledergerber B. et al., 2017/02/15. Clinical infectious diseases, 64 (4) pp. 490-497. Peer-reviewed.
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population.
Gueler A., Moser A., Calmy A., Günthard H.F., Bernasconi E., Furrer H., Fux C.A., Battegay M., Cavassini M., Vernazza P. et al., 2017/01/28. AIDS, 31 (3) pp. 427-436. Peer-reviewed.
Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.
Chereau F., Madec Y., Sabin C., Obel N., Ruiz-Mateos E., Chrysos G., Fidler S., Lehmann C., Zangerle R., Wittkop L. et al., 2017. PloS one, 12 (4) pp. e0173893. Peer-reviewed.
Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study.
De Rossi N., Dattner N., Cavassini M., Peters S., Hugli O., Darling KEA, 2017. PloS one, 12 (7) pp. e0180389. Peer-reviewed.
The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment.
Kamal S., Locatelli I., Wandeler G., Sehhat A., Bugnon O., Metral M., Du Pasquier R., Gutbrod K., Cavassini M., Schneider M.P. et al., 2017. Open forum infectious diseases, 4 (2) pp. ofx070. Peer-reviewed.
 
Determinants of HIV-1 broadly neutralizing antibody induction.
Rusert P., Kouyos R.D., Kadelka C., Ebner H., Schanz M., Huber M., Braun D.L., Hozé N., Scherrer A., Magnus C. et al., 2016/11. Nature medicine, 22 (11) pp. 1260-1267. Peer-reviewed.
CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART.
Sauter R., Huang R., Ledergerber B., Battegay M., Bernasconi E., Cavassini M., Furrer H., Hoffmann M., Rougemont M., Günthard H.F. et al., 2016/10. Medicine, 95 (42) pp. e5094. Peer-reviewed.
 
Development of an algorithm for analysing the electronic measurement of medication adherence in routine HIV care.
Rotzinger A., Cavassini M., Bugnon O., Schneider M.P., 2016/10. International journal of clinical pharmacy, 38 (5) pp. 1210-1218. Peer-reviewed.
 
Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I.
Merz L., Zimmermann S., Peters S., Cavassini M., Darling K.E., 2016/10. The oncologist, 21 (10) pp. 1176-1182. Peer-reviewed.
Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared.
Wandeler G., Mulenga L., Vinikoor M.J., Kovari H., Battegay M., Calmy A., Cavassini M., Bernasconi E., Schmid P., Bolton-Moore C. et al., 2016/10. International journal of infectious diseases, 51 pp. 97-102. Peer-reviewed.
 
Médecine d’urgence et prévention : une antinomie ? Réflexion à partir du dépistage VIH [Emergency medicine and prevention : a contradiction in terms ? Observations based on HIV screening]
Hugli O., Tagliabue L., Cavassini M., Darling K., 2016/08/10. Revue medicale suisse, 12 (526) pp. 1331-1335. Peer-reviewed.
 
Association of disclosure of HIV status with medication adherence.
Rotzinger A., Locatelli I., Reymermier M., Amico S., Bugnon O., Cavassini M., Schneider M.P., 2016/08. Patient education and counseling, 99 (8) pp. 1413-1420. Peer-reviewed.
 
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Fuchs A., Rotzinger A., Cavassini M., Bugnon O., Buclin T., Schneider M.P., Csajka C., 2016/08. Therapeutic drug monitoring, 38 (4) pp. 506-515. Peer-reviewed.
 
Privacy-preserving genomic testing in the clinic: a model using HIV treatment.
McLaren P.J., Raisaro J.L., Aouri M., Rotger M., Ayday E., Bartha I., Delgado M.B., Vallet Y., Günthard H.F., Cavassini M. et al., 2016/08. Genetics in medicine, 18 (8) pp. 814-822. Peer-reviewed.
 
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study.
Scherrer A.U., Yang W.L., Kouyos R.D., Böni J., Yerly S., Klimkait T., Aubert V., Cavassini M., Battegay M., Hauser C. et al., 2016/08/01. The Journal of infectious diseases, 214 (3) pp. 399-402. Peer-reviewed.
 
PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals.
Banga R., Procopio F.A., Noto A., Pollakis G., Cavassini M., Ohmiti K., Corpataux J.M., de Leval L., Pantaleo G., Perreau M., 2016/07. Nature medicine, 22 (7) pp. 754-761. Peer-reviewed.
 
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C., Gaspar F., Aouri M., Panchaud A., Rotger M., Guidi M., Cavassini M., Buclin T., Decosterd L.A., Csajka C. et al., 2016/07. The Journal of antimicrobial chemotherapy, 71 (7) pp. 1933-1942. Peer-reviewed.
Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland.
Shilaih M., Marzel A., Yang W.L., Scherrer A.U., Schüpbach J., Böni J., Yerly S., Hirsch H.H., Aubert V., Cavassini M. et al., 2016/06/14. Scientific reports, 6 p. 27580. Peer-reviewed.
 
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis.
Scherrer A.U., von Wyl V., Yang W.L., Kouyos R.D., Böni J., Yerly S., Klimkait T., Aubert V., Cavassini M., Battegay M. et al., 2016/05/15. Clinical infectious diseases, 62 (10) pp. 1310-1317. Peer-reviewed.
 
Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.
Rotzinger A., Locatelli I., Bugnon O., Fayet Mello A., Parienti J.J., Cavassini M., Schneider M.P., 2016/05. HIV medicine, 17 (5) pp. 390-396. Peer-reviewed.
Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study.
Elzi L., Conen A., Patzen A., Fehr J., Cavassini M., Calmy A., Schmid P., Bernasconi E., Furrer H., Battegay M., 2016. Open Forum Infectious Diseases, 3 (1) pp. ofw022. Peer-reviewed.
Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy.
Trickey A., May M.T., Vehreschild J., Obel N., Gill M.J., Crane H., Boesecke C., Samji H., Grabar S., Cazanave C. et al., 2016. PloS one, 11 (8) pp. e0160460. Peer-reviewed.
 
Hepatitis C Virus Awareness Among Men Who Have Sex With Men in Southwest Switzerland.
Clerc O., Darling K., Calmy A., Dubois-Arber F., Cavassini M., 2016. Sexually Transmitted Diseases, 43 (1) pp. 44-48. Peer-reviewed.
 
HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study.
Marzel A., Shilaih M., Yang W.L., Böni J., Yerly S., Klimkait T., Aubert V., Braun D.L., Calmy A., Furrer H. et al., 2016. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 62 (1) pp. 115-122. Peer-reviewed.
 
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M., Barcelo C., Ternon B., Cavassini M., Anagnostopoulos A., Yerly S., Hugues H., Vernazza P., Günthard H.F., Buclin T. et al., 2016. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 44 (1) pp. 151-161.
Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better.
Darling K.E., Hachfeld A., Cavassini M., Kirk O., Furrer H., Wandeler G., 2016. Swiss medical weekly, 146 pp. w14348. Peer-reviewed.
Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study.
May M.T., Vehreschild J.J., Trickey A., Obel N., Reiss P., Bonnet F., Mary-Krause M., Samji H., Cavassini M., Gill M.J. et al., 2016. Clinical Infectious Diseases, 62 (12) pp. 1571-1577. Peer-reviewed.
 
Postnatal retention in HIV care : insight from the Swiss HIV Cohort Study over a 15-year observational period
Aebi-Popp K., Kouyos R., Bertisch B., Staehelin C., Rudin C., Hoesli I., Stoeckle M., Bernasconi E., Cavassini M., Grawe C. et al., 2016. Hiv Medicine, 17 (4) pp. 280-288.
 
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.
Mills A., Arribas J.R., Andrade-Villanueva J., DiPerri G., Van Lunzen J., Koenig E., Elion R., Cavassini M., Madruga J.V., Brunetta J. et al., 2016. Lancet. Infectious Diseases, 16 (1) pp. 43-52.
Cryptococcus neoformans meningitis with negative cryptococcal antigen: Evaluation of a new immunochromatographic detection assay.
Opota O., Desgraz B., Kenfak A., Jaton K., Cavassini M., Greub G., Prod'hom G., Giulieri S., 2015/12. New Microbes and New Infections, 4 pp. 1-4. Peer-reviewed.
 
Vitamin D time profile based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry.
Guidi M., Foletti G., McLaren P., Cavassini M., Rauch A., Tarr P.E., Lamy O., Panchaud A., Telenti A., Csajka C. et al., 2015/07. Antiviral Therapy, 20 (3) pp. 261-269. Peer-reviewed.
 
Establishment of a multi-disciplinary platform for HIV-infected patients with neurological complications.
du Pasquier R., Simioni S., Alves D., Meuli R., Maccaferri G.E., Berney A., Cavassini M., 2015/04/08. p. 88 dans Scientific Abstract Listing of the 66th Annual Meeting, , Neurology. Peer-reviewed, American Academy of Neurology (AAN).
 
Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study.
Yang W.L., Kouyos R.D., Scherrer A.U., Böni J., Shah C., Yerly S., Klimkait T., Aubert V., Hirzel C., Battegay M. et al., 2015. Journal of Antimicrobial Chemotherapy, 70 (12) pp. 3323-3331. Peer-reviewed.
 
Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012.
Yang W.L., Kouyos R., Scherrer A.U., Böni J., Shah C., Yerly S., Klimkait T., Aubert V., Furrer H., Battegay M. et al., 2015. Journal of Infectious Diseases, 212 (1) pp. 28-38. Peer-reviewed.
 
Consultations infectiologiques ambutatoires non VIH: analyse d'un centre universitaire sur cinq ans [Non-HIV infectious disease outpatient consultations: a 5-year study in a Swiss University Hospital].
Flückiger N., Moulin E., Merz L., Darling K., Cavassini M., 2015. Revue Médicale Suisse, 11 (470) pp. 850-855.
 
Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.
Young J., Xiao Y., Moodie E.E., Abrahamowicz M., Klein M.B., Bernasconi E., Schmid P., Calmy A., Cavassini M., Cusini A. et al., 2015. Journal of Acquired Immune Deficiency Syndromes (1999), 69 (4) pp. 413-421. Peer-reviewed.
 
Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study.
Rosin C., Elzi L., Thurnheer C., Fehr J., Cavassini M., Calmy A., Schmid P., Bernasconi E., Battegay M., 2015. Hiv Medicine, 16 (5) pp. 319-325. Peer-reviewed.
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Bihl F., Martinetti G., Wandeler G., Weber R., Ledergeber B., Calmy A., Battegay M., Cavassini M., Vernazza P., Caminada A.P. et al., 2015. Bmc Gastroenterology, 15 p. 79. Peer-reviewed.
 
High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013.
Kovari H., Ledergerber B., Cavassini M., Ambrosioni J., Bregenzer A., Stöckle M., Bernasconi E., Kouyos R., Weber R., Rauch A. et al., 2015. Journal of Hepatology, 63 (3) pp. 573-580. Peer-reviewed.
 
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.
Antiretroviral Therapy Cohort Collaboration (ART-CC), 2015. Aids, 29 (3) pp. 373-383. Peer-reviewed.
In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R., Procopio F.A., Cavassini M., Perreau M., 2015. Journal of Virology, 90 (4) pp. 1858-1871.
[DOI] [WoS] [Pmid] [serval:BIB_62D9248CFA28]
Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study : changes in treatment uptake and outcomes between 1991 and 2013
Wandeler G., Schlauri M., Jaquier M.E., Rohrbach J., Metzner K.J., Fehr J., Ambrosioni J., Cavassini M., Stöckle M., Schmid P. et al., 2015. Open Forum Infectious Diseases, 2 (1) pp. ofv026.
Increases in condomless sex in the Swiss HIV Cohort Study.
Kouyos R.D., Hasse B., Calmy A., Cavassini M., Furrer H., Stöckle M., Vernazza P.L., Bernasconi E., Weber R., Günthard H.F. et al., 2015. Open Forum Infectious Diseases, 2 (2) pp. ofv077. Peer-reviewed.
 
Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland.
Gueler A., Schoeni-Affolter F., Moser A., Bertisch B., Bucher H.C., Calmy A., Cavassini M., Ledergerber B., Wandeler G., Egger M. et al., 2015. Aids, 29 (2) pp. 231-238. Peer-reviewed.
 
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
Molina J.M., Clotet B., van Lunzen J., Lazzarin A., Cavassini M., Henry K., Kulagin V., Givens N., de Oliveira C.F., Brennan C. et al., 2015. Lancet. Hiv, 2 (4) pp. e127-e136. Peer-reviewed.
Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study.
Favre-Bulle T., Baudat D., Darling K., Mamin R., Peters S., Cavassini M., Hugli O., 2015. Swiss Medical Weekly, 145 pp. w14206. Peer-reviewed.
 
Performance of the 47-kilodalton membrane protein versus DNA polymerase I genes for detection of Treponema pallidum by PCR in ulcers.
Gayet-Ageron A., Laurent F., Schrenzel J., Charton B., Jimenez-Getaz G., Tangomo M., Ferry T., Sednaoui P., Lautenschlager S., Toutous-Trellu L. et al., 2015. Journal of Clinical Microbiology, 53 (3) pp. 976-980. Peer-reviewed.
 
Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study.
Schäfer J., Young J., Bernasconi E., Ledergerber B., Nicca D., Calmy A., Cavassini M., Furrer H., Battegay M., Bucher H. et al., 2015. Hiv Medicine, 16 (1) pp. 3-14. Peer-reviewed.
 
Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.
Schaerer V., Haubitz S., Kovari H., Ledergerber B., Ambrosioni J., Cavassini M., Stoeckle M., Schmid P., Decosterd L., Aouri M. et al., 2015. HIV Medicine, 16 (10) pp. 599-607. Peer-reviewed.
Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
Kovari H., Russmann S., Ledergerber B., Müller D., Rotger M., Velli P., Cavassini M., Ambrosioni J., Bregenzer A., Stöckle M. et al., 2015. Plos One, 10 (7) pp. e0133879. Peer-reviewed.
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America.
Helleberg M., May M.T., Ingle S.M., Dabis F., Reiss P., Fätkenheuer G., Costagliola D., d'Arminio A., Cavassini M., Smith C. et al., 2015. Aids, 29 (2) pp. 221-229. Peer-reviewed.
Strong impact of smoking on multimorbidity and cardiovascular risk among human immunodeficiency virus-infected individuals in comparison with the general population.
Hasse B., Tarr P.E., Marques-Vidal P., Waeber G., Preisig M., Mooser V., Valeri F., Djalali S., Andri R., Bernasconi E. et al., 2015. Open Forum Infectious Diseases, 2 (3) pp. ofv108. Peer-reviewed.
 
Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
Ciaffi L., Cavassini M., Genne D., Delhumeau C., Spycher Elbes R., Hill A., Wandeler G., Fehr J., Stoeckle M., Schmid P. et al., 2015. European Journal of Clinical Investigation, 45 (7) pp. 720-730. Peer-reviewed.
 
The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV.
Kohler P., Schmidt A.J., Cavassini M., Furrer H., Calmy A., Battegay M., Bernasconi E., Ledergerber B., Vernazza P., Swiss HIV Cohort Study, 2015. Aids (london, England), 29 (18) pp. 2509-2515. Peer-reviewed.
Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study.
Young J., Rickenbach M., Calmy A., Bernasconi E., Staehelin C., Schmid P., Cavassini M., Battegay M., Günthard H.F., Bucher H.C. et al., 2015. Bmc Infectious Diseases, 15 (1) p. 382. Peer-reviewed.
Use of Treponema pallidum PCR in Testing of Ulcers for Diagnosis of Primary Syphilis(1.).
Gayet-Ageron A., Sednaoui P., Lautenschlager S., Ferry T., Toutous-Trellu L., Cavassini M., Yassir F., Martinez de Tejada B., Emonet S., Combescure C. et al., 2015. Emerging Infectious Diseases, 21 (1) pp. 127-129. Peer-reviewed.
 
Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study.
Boillat-Blanco N., Darling K.E., Schoni-Affolter F., Vuichard D., Rougemont M., Fulchini R., Bernasconi E., Aouri M., Clerc O., Furrer H. et al., 2015. Antiviral Therapy, 20 (2) pp. 165-175. Peer-reviewed.
 
A-24: Modification de la thérapie antirétrovirale en alternative au traitement par statines pour les patients séropositifs pour le VIH présentant un risque cardiovasculaire bas ou intermédiaire : l'essai prospectif ETRALL [In Process Citation].
Médecine et Maladies Infectieuses (eds.), 2014., 44 1.
AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be.
Gisler V., Kraus D., Nemeth J., Lecompte M.T., Merz L., Stoeckle M., Schmid P., Bernasconi E., Weber R., Cavassini M. et al., 2014. Journal of the International Aids Society, 17 (4 Suppl 3) p. 19621. Peer-reviewed.
 
Antiretrovirale Therapie [Antiretroviral therapy].
von Braun A., Furrer H., Battegay M., Calmy A., Cavassini M., Vernazza P., Bernasconi E., Weber R., Günthard H.F., 2014. Therapeutische Umschau. Revue Thérapeutique, 71 (8) pp. 461-468. Peer-reviewed.
Asking about adherence - from flipping the coin to strong evidence.
Glass T., Cavassini M., 2014. Swiss Medical Weekly, 144 pp. w14016. Peer-reviewed.
 
Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals.
Rohrbach J., Stickel F., Schmid P., Thormann W., Kovari H., Scherrer A., Günthard H.F., Vuichard D., Cavassini M., Ambrosioni J. et al., 2014. Antiviral Therapy, 19 (2) pp. 149-159.
[DOI] [Pmid] [serval:BIB_8D6338AAE8DD]
 
Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals.
Rohrbach J., Stickel F., Schmid P., Thormann W., Kovari H., Scherrer A., Günthard H.F., Vuichard D., Cavassini M., Ambrosioni J. et al., 2014. Antiviral Therapy, 19 (2) pp. 149-159.
 
Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV.
Kouyos R.D., Rauch A., Böni J., Yerly S., Shah C., Aubert V., Klimkait T., Kovari H., Calmy A., Cavassini M. et al., 2014. International Journal of Epidemiology, 43 (3) pp. 887-896. Peer-reviewed.
 
Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).
May M.T., Ingle S.M., Costagliola D., Justice A.C., de Wolf F., Cavassini M., D'Arminio Monforte A., Casabona J., Hogg R.S., Mocroft A. et al., 2014. International Journal of Epidemiology, 43 (3) pp. 691-702. Peer-reviewed.
 
Complications of infective endocarditis
Giulieri S., Meuli R., Cavassini M., 2014. pp. 579-607 dans Wolters Kluwer Health (eds.) Infections of the central nervous system chap. 34, Scheld W. Michael Whitley Richard J. Marra Christina M..
Dynamics of HIV latency and reactivation in a primary CD4+ T cell model.
Mohammadi P., di Iulio J., Muñoz M., Martinez R., Bartha I., Cavassini M., Thorball C., Fellay J., Beerenwinkel N., Ciuffi A. et al., 2014. Plos Pathogens, 10 (5) pp. e1004156.
 
Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide.
Kouyos R.D., Rauch A., Braun D.L., Yang W.L., Böni J., Yerly S., Klimkait T., Aubert V., Shah C., Kovari H. et al., 2014. Journal of Infectious Diseases, 210 (10) pp. 1555-1561. Peer-reviewed.
HIV-1 superinfection with a triple-class drug-resistant strain in a patient successfully controlled with antiretroviral treatment.
Castro E., Zhao H., Cavassini M., Mullins J.I., Pantaleo G., Bart P.A., 2014. Aids, 28 (12) pp. 1840-1844. Peer-reviewed.
Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.
Ingle S.M., May M.T., Gill M.J., Mugavero M.J., Lewden C., Abgrall S., Fätkenheuer G., Reiss P., Saag M.S., Manzardo C. et al., 2014. Clinical Infectious Diseases, 59 (2) pp. 287-297. Peer-reviewed.
Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I.
Merz L., Peters S., Zimmermann S., Cavassini M., Darling K., 2014. p. 19622 dans Abstracts of the HIV Drug Therapy Glasgow Congress 2014, Journal of the International Aids Society. Peer-reviewed.
 
Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
Metzner K.J., Scherrer A.U., von Wyl V., Böni J., Yerly S., Klimkait T., Aubert V., Furrer H., Hirsch H.H., Vernazza P.L. et al., 2014. Aids, 28 (15) pp. 2231-2239. Peer-reviewed.
Loss to follow-up of HIV-infected women after delivery : The Swiss HIV Cohort Study and the Swiss Mother and Child HIV Cohort Study
Aebi-Popp K., Kouyos R., Bertisch B., Staehelin C., Hoesli I., Rickenbach M., Thorne C., Grawe C., Bernasconi E., Cavassini M. et al., 2014. p. 19535 dans Journal of the International AIDS Society. Peer-reviewed.
 
Maladies infectieuses [Infectious diseases].
Voide C., Asner S., Giulieri S., Cavassini M., Merz L., Tissot F., Orasch C., 2014. Revue Médicale Suisse, 10 (412-413) pp. 61-65.
Obesity trends and body mass index changes after starting antiretroviral treatment : the Swiss HIV Cohort Study
Hasse B., Iff M., Ledergerber B., Calmy A., Schmid P., Hauser C., Cavassini M., Bernasconi E., Marzolini C., Tarr P.E. et al., 2014. Open Forum Infectious Diseases, 1 (2) pp. ofu040.
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO.
Molina J.M., Clotet B., van Lunzen J., Lazzarin A., Cavassini M., Henry K., Kulagin V., Givens N., Brennan C., de Oliveira C.F., 2014. Journal of the International Aids Society, 17 (4 Suppl 3) p. 19490. Peer-reviewed.
Patients with AIDS-defining cancers are not universally screened for HIV: a 10-year retrospective analysis of HIV-testing practices in a Swiss university hospital.
Mosimann V., Cavassini M., Hugli O., Mamin R., Achtari C., Peters S., Darling K.E., 2014. Hiv Medicine, 15 (10) pp. 631-634. Peer-reviewed.
 
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M., Lubomirov R., Fayet-Mello A., Aouri M., Rotger M., Buclin T., Widmer N., Gatri M., Ledergerber B., Rentsch K. et al., 2014. Journal of Antimicrobial Chemotherapy, 69 (9) pp. 2489-2498. Peer-reviewed.
 
Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme.
Krummenacher I., Spencer B., Du Pasquier S., Bugnon O., Cavassini M., Schneider M.P., 2014. International Journal of Clinical Pharmacy, 36 (4) pp. 716-724. Peer-reviewed.
 
Réplication cérébrale du VIH malgré une thérapie antirétrovirale efficace: impact clinique et prise en charge [Intracerebral HIV replication despite an efficient antiretroviral treatment: clinical impact and management].
Schibler M., Calmy A., Cavassini M., Du Pasquier R., 2014. Revue Médicale Suisse, 10 (427) pp. 908, 910-908, 912. Peer-reviewed.
 
Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
Thacher E.G., Cavassini M., Audran R., Thierry A.C., Bollaerts A., Cohen J., Demoitié M.A., Ejigu D., Mettens P., Moris P. et al., 2014. Aids, 28 (12) pp. 1769-1781. Peer-reviewed.
 
Secret professionnel et maladies infectieuses
Simon Jeanne-Pascale, Cavassini Matthias, Lazor-Blanchet Catherine, 2014. pp. 341-350 dans La Harpe Romano, Ummel Marinette, Dumoulin Jean-François (eds.) Droit de la Santé et Médecine Légale, Médecine et Hygiène.
 
Seroprevalence of hepatitis e virus in domestic pigs and wild boars in Switzerland.
Burri C., Vial F., Ryser-Degiorgis M.P., Schwermer H., Darling K., Reist M., Wu N., Beerli O., Schöning J., Cavassini M. et al., 2014. Zoonoses and Public Health, 61 (8) pp. 537-544. Peer-reviewed.
 
Sinusite aiguë
Rodondi P.Y., Pasche O., Kermode-Noppel T., Cornuz J., Cavassini M., Senn L., Barras F., Pasche P., 2014. pp. 238-245 dans COMPAS : Stratégies de Prise en Charge Clinique : Médecine Interne Générale Ambulatoire chap. 16, Médecine et Hygiène.
 
The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients.
Bibert S., Wojtowicz A., Taffé P., Manuel O., Bernasconi E., Furrer H., Günthard H.F., Hoffmann M., Kaiser L., Osthoff M. et al., 2014. Aids (london, England), 28 (13) pp. 1885-1889. Peer-reviewed.
 
The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.
Young J., Wang Q., Fux C., Bernasconi E., Furrer H., Vernazza P., Calmy A., Cavassini M., Weber R., Battegay M. et al., 2014. Hiv Medicine, 15 (8) pp. 505-510. Peer-reviewed.
 
Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study.
Drescher S.M., von Wyl V., Yang W.L., Böni J., Yerly S., Shah C., Aubert V., Klimkait T., Taffé P., Furrer H. et al., 2014. Clinical Infectious Diseases, 58 (2) pp. 285-294.
 
Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone.
Wang Q., Young J., Bernasconi E., Vernazza P., Calmy A., Cavassini M., Furrer H., Fehr J., Bucher H.C., Battegay M. et al., 2014. HIV Clinical Trials, 15 (3) pp. 92-103.
 
A light in the cognitive fog?
Cavassini M., Du Pasquier R.A., 2013. Antiviral Therapy, 18 (2) pp. 149-151. Peer-reviewed.
 
A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M., Calmy A., Hirschel B., Telenti A., Buclin T., Cavassini M., Rauch A., Decosterd L.A., 2013. Journal of Mass Spectrometry, 48 (5) pp. 616-625.
Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study.
von Wyl V., Klimkait T., Yerly S., Nicca D., Furrer H., Cavassini M., Calmy A., Bernasconi E., Böni J., Aubert V. et al., 2013. Plos One, 8 (10) pp. e77691.
 
Adherence to antiretroviral treatment decreases during postpartum compared to pregnancy: a longitudinal electronic monitoring study.
Gertsch A., Michel O., Locatelli I., Bugnon O., Rickenbach M., Cavassini M., Schneider M.P., 2013. AIDS Patient Care and STDs, 27 (4) pp. 208-210.
An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population.
Schnegg A., Bürgisser P., André C., Kenfak-Foguena A., Canellini G., Moradpour D., Abravanel F., Izopet J., Cavassini M., Darling K.E., 2013. Plos One, 8 (5) pp. e62980.
Awareness of HIV Testing Guidelines Is Low among Swiss Emergency Doctors: A Survey of Five Teaching Hospitals in French-Speaking Switzerland.
Darling K.E., de Allegri N., Fishman D., Kehtari R., Rutschmann O.T., Cavassini M., Hugli O., 2013. Plos One, 8 (9) pp. e72812.
 
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study.
Weber R., Ruppik M., Rickenbach M., Spoerri A., Furrer H., Battegay M., Cavassini M., Calmy A., Bernasconi E., Schmid P. et al., 2013. HIV Medicine, 14 (4) pp. 195-207. Peer-reviewed.
 
Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women.
Fayet-Mello A., Buclin T., Guignard N., Cruchon S., Cavassini M., Grawe C., Gremlich E., Popp K.A., Schmid F., Eap C.B. et al., 2013. Antiviral Therapy, 18 (2) pp. 171-182. Peer-reviewed.
 
Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study.
Wandeler G., Gsponer T., Bihl F., Bernasconi E., Cavassini M., Kovari H., Schmid P., Battegay M., Calmy A., Egger M. et al., 2013. Journal of Infectious Diseases, 208 (9) pp. 1454-1458.
 
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Cusini A., Vernazza P.L., Yerly S., Decosterd L.A., Ledergerber B., Fux C.A., Rohrbach J., Widmer N., Hirschel B., Gaudenz R. et al., 2013. Journal of Acquired Immune Deficiency Syndromes, 62 (1) pp. 28-35. Peer-reviewed.
HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis.
Fenner L., Egger M., Bodmer T., Furrer H., Ballif M., Battegay M., Helbling P., Fehr J., Gsponer T., Rieder H.L. et al., 2013. Plos Genetics, 9 (3) pp. e1003318.
 
Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study.
Boillat-Blanco N., Darling K.E., Taffe P., Osih R., Strahm C., Adami M., Elzi L., Daou S., Fehr J., Wandeler G. et al., 2013. Journal of Acquired Immune Deficiency Syndromes, 62 (2) pp. 180-189. Peer-reviewed.
 
Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy.
Du Pasquier R.A., Jilek S., Kalubi M., Yerly S., Fux C.A., Gutmann C., Cusini A., Günthard H.F., Cavassini M., Vernazza P.L. et al., 2013. Aids, 27 (2) pp. 203-210. Peer-reviewed.
Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High Field.
Granziera C., Daducci A., Simioni S., Cavassini M., Roche A., Meskaldji D., Kober T., Metral M., Calmy A., Helms G. et al., 2013. Plos One, 8 (9) pp. e72547.
 
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Aouri M., Moradpour D., Cavassini M., Mercier T., Buclin T., Csajka C., Telenti A., Rauch A., Decosterd L.A., 2013. Antimicrobial Agents and Chemotherapy, 57 (7) pp. 3147-3158. Peer-reviewed.
 
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.
Metzner K.J., Scherrer A.U., Preiswerk B., Joos B., von Wyl V., Leemann C., Rieder P., Braun D., Grube C., Kuster H. et al., 2013. Journal of Infectious Diseases, 208 (7) pp. 1102-1112.
 
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R., Arab-Alameddine M., Rotger M., Fayet-Mello A., Martinez R., Guidi M., di Iulio J., Cavassini M., Günthard H.F., Furrer H. et al., 2013. Pharmacogenetics and Genomics, 23 (1) pp. 9-18. Peer-reviewed.
Rapid Perturbation in Viremia Levels Drives Increases in Functional Avidity of HIV-specific CD8 T Cells.
Viganò S., Bellutti Enders F., Miconnet I., Cellerai C., Savoye A.L., Rozot V., Perreau M., Faouzi M., Ohmiti K., Cavassini M. et al., 2013. Plos Pathogens, 9 (7) pp. e1003423.
 
Risk Factors for Anal Cancer in Persons Infected With HIV: A Nested Case-Control Study in the Swiss HIV Cohort Study.
Bertisch B., Franceschi S., Lise M., Vernazza P., Keiser O., Schöni-Affolter F., Bouchardy C., Dehler S., Levi F., Jundt G. et al., 2013. American Journal of Epidemiology, 178 (6) pp. 877-884. Peer-reviewed.
 
Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS).
Nüesch R., Wang Q., Elzi L., Bernasconi E., Weber R., Cavassini M., Vernazza P., Thurnheer M.C., Calmy A., Battegay M. et al., 2013. Journal of Acquired Immune Deficiency Syndromes (1999), 62 (4) pp. 396-404. Peer-reviewed.
 
Rivastigmine for HIV-associated neurocognitive disorders: A randomized crossover pilot study.
Simioni S., Cavassini M., Annoni J.M., Métral M., Iglesias K., Rimbault Abraham A., Jilek S., Calmy A., Müller H., Fayet-Mello A. et al., 2013. Neurology, 80 (6) pp. 553-560.
 
Suboptimal access to primary healthcare among street-based sex workers in southwest Switzerland.
Darling K.E., Gloor E., Ansermet-Pagot A., Vaucher P., Durieux-Paillard S., Bodenmann P., Cavassini M., 2013. Postgraduate Medical Journal, 89 (1053) pp. 371-375. Peer-reviewed.
The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients.
Beerenwinkel N., Montazeri H., Schuhmacher H., Knupfer P., von Wyl V., Furrer H., Battegay M., Hirschel B., Cavassini M., Vernazza P. et al., 2013. PLOS Computational Biology, 9 (8) pp. e1003203.
 
The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study.
Wang Q., Young J., Bernasconi E., Cavassini M., Vernazza P., Hirschel B., Weber R., Furrer H., Stoeckle M., Bucher H.C. et al., 2013. Antiviral Therapy, 18 (3) pp. 337-344.
 
Ultra-adherence with Electronic Pills-box may Reveal Poor Adherence
Schneider Marie P., Cavassini Matthias, Bugnon Olivier, Senn Nicolas, 2013. Journal of General Practice, 01 (04). Peer-reviewed.
 
Voyages et VIH: les points-clés [Key aspects regarding HIV and travel].
Gardiol C., Cavassini M., 2013. Revue Médicale Suisse, 9 (385) pp. 963-967.
 
First-line antiretroviral treatment outcome in a patient presenting an HIV-1/2 multiclass drug resistant infection
Castro E, Recordon-Pinson P, Papuchon J, Vetter B, Shah C, Schupbach J, Fleury H, Cavassini M, 2012/11/11., 11th International Congress on Drug Therapy in HIV Infection dans Journal of the International AIDS Society, International AIDS Society.
A comparison of three anti-HEV IgG EIA screening kits and one confirmatory immunodot assay in blood donor samples in Switzerland
Schnegg A., Bürgisser P., André C., Kenfak-Foguena A., Canellini G., Moradpour D., Darling K.E.A., Cavassini M., 2012. dans ICAAC 2012, 52nd of the Interscience Conference on Antimicrobial Agents and Chemotherapy.
 
A cross-sectional survey of attitudes to HIV risk and rapid HIV testing among clients of sex workers in Switzerland.
Darling K.E., Diserens E.A., N'garambe C., Ansermet-Pagot A., Masserey E., Cavassini M., Bodenmann P., 2012. Sexually Transmitted Infections, 88 (6) pp. 462-464.
 
A dynamic assessment of medication-taking behavior during pregnancy and postpartum: should cART adherence be reinforced during postpartum?
Michel O., Gertsch A., Locatelli I., Cavassini M., Rickenbach M., Bugnon O., Schneider M., 2012. p. 36 dans 11th International Congress on Drug Therapy in HIV Infection, Journal of the International AIDS Society.
 
An analysis of patients' understanding of 'routine' preoperative blood tests and HIV screening. Is no news really good news?
Albrecht E., Frascarolo P., Meystre-Agustoni G., Farron A., Gilliard N., Darling K., Cavassini M., 2012. HIV Medicine, 13 (7) pp. 439-443. Peer-reviewed.
 
Awareness of HIV Screening Guidelines and HIV testing are low in Swiss emergency departements
Hugli O., de Allegri N., Darling K.E.A., Cavassini M., 2012. pp. S295 dans 2012 Annual Meeting of the Society for Academic Emergency Medicine, Academic Emergency Medicine.
 
Awareness of human immunodeficiency virus screening guidelines is low in emergency departments of western Switzerland.
de Allegri N., Darling K.E.A., Cavassini M., Fishmann D., Garcia W., Kehtari R., Rutschmann O., Hugli O., 2012. pp. 15S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum.
 
Characteristics of HIV patients referred to a medication adherence program in Switzerland.
Krummenacher I., Cavassini M., Bugnon O., Schneider M.P., 2012. International Journal of Clinical Pharmacy, 34 (3) pp. 426-431.
 
Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.
Elzi L., Erb S., Furrer H., Ledergerber B., Cavassini M., Hirschel B., Vernazza P., Bernasconi E., Weber R., Battegay M. et al., 2012. Archives of Internal Medicine, 172 (17) pp. 1313-1321.
 
Dépistage et connaissance de l'hépatite C chez les hommes qui ont des rapports sexuels avec des hommes dans la région lémanique
Clerc O., Jeannin A., Darling K., Boffi El Amari E., Jobin V., Calmy A., Dubois-Arber F., Cavassini M., 2012. dans AFRAVIH 2012, 6e Conférence Francophone VIH/SIDA.
Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.
Siegrist C.A., van Delden C., Bel M., Combescure C., Delhumeau C., Cavassini M., Clerc O., Meier S., Hadaya K., Soccal P.M. et al., 2012. Plos One, 7 (7) pp. e40428. Peer-reviewed.
HIV Testing Practices by Clinical Service before and after Revised Testing Guidelines in a Swiss University Hospital.
Darling K.E., Hugli O., Mamin R., Cellerai C., Martenet S., Berney A., Peters S., Du Pasquier R.A., Bodenmann P., Cavassini M., 2012. Plos One, 7 (6) pp. e39299. Peer-reviewed.
 
Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen.
Kaech C., Pache I., Bürgisser P., Elzi L., Darling K.E., Cavassini M., 2012. Journal of Infection, 65 (2) pp. 157-164.
 
Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.
von Wyl V., Yerly S., Böni J., Shah C., Cellerai C., Klimkait T., Battegay M., Bernasconi E., Cavassini M., Furrer H. et al., 2012. Clinical Infectious Diseases, 54 (1) pp. 131-140.
 
Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection.
Delaloye J., De Bruin I.J., Darling K.E., Reymond M.K., Sweep F.C., Roger T., Calandra T., Cavassini M., 2012. Cytokine, 60 (2) pp. 338-340. Peer-reviewed.
 
Les urgentistes n'identifient pas les patients à haut risque d'infection HIV.
Hugli O., de Allegri N., Fishman D., Garcia W., Kehtari R., Rutschmann O., Darling K., Cavassini M., 2012. dans Urgences 2012, 6e Congrès de la Société Française de Médecine (SFMU).
Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens.
Scherrer A.U., Böni J., Yerly S., Klimkait T., Aubert V., Furrer H., Calmy A., Cavassini M., Elzi L., Vernazza P.L. et al., 2012. Plos One, 7 (11) pp. e50307.
 
Long-term close follow-up of chorioretinal lesions in presumed ocular tuberculosis.
Ducommun M.A., Eperon S., Khonkarly M.B., Cavassini M., Guex-Crosier Y., 2012. European Journal of Ophthalmology, 22 (2) pp. 195-202. Peer-reviewed.
 
Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study.
Staehelin C., Keiser O., Calmy A., Weber R., Elzi L., Cavassini M., Schmid P., Bernasconi E., Furrer H., Swiss HIV Cohort Study, 2012. Journal of Acquired Immune Deficiency Syndromes, 59 (1) pp. 79-85.
 
Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection.
Clifford G.M., Lise M., Franceschi S., Egger M., Bouchardy C., Korol D., Levi F., Ess S., Jundt G., Wandeler G. et al., 2012. British Journal of Cancer, 106 (3) pp. 447-452. Peer-reviewed.
Microstructural alterations in the brain of well treated HIV+ patients with minor neurocognitive disorders: a multi-contrast MRI study at 3T
Granziera C., Daducci A., Simioni S., Cavassini M., Roche A., Meskaldji D.E., Michel M., Calmy A., Hirschel B., Krüger G. et al., 2012. p. 4790 dans ISMRM 2012, 20th Annual Meeting and Exhibition of the International Society for Magnetic Resonance in Medicine, SMRT 21st Annual Meeting of the Section for Magnetic Resonance Technologists conference, Proceedings of the International Society for Magnetic Resonance in Medicine.
 
Microstructural alterations in the brain of well treated HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field
Granziera Cristina, Daducci Alessandro, Simioni Samanta, Cavassini M., Roche Alexis, Meskaldji Djalel Eddine, Michel M., Calmy A., Hirschel B., Krüger Gunnar et al., 2012. pp. -- dans Neurology.
[serval:BIB_5D3FD1C7C8F8]
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
Scherrer A.U., Ledergerber B., von Wyl V., Böni J., Yerly S., Klimkait T., Cellerai C., Furrer H., Calmy A., Cavassini M. et al., 2012. Plos One, 7 (6) pp. e37983.
Multiclass primary antiretroviral drug resistance in a patient presenting HIV-1/2 dual infection.
Castro E., Recordon-Pinson P., Cavassini M., Fleury H., 2012. Antiviral Therapy, 17 (3) pp. 593-594. Peer-reviewed.
 
Mycobacterium chelonae illnesses associated with tattoo ink.
Giulieri S., Cavassini M., Jaton K., 2012. New England Journal of Medicine, 367 (24) pp. 2357-2358.
 
Nonrandom Distribution of Cryptic Repeating Triplets of Purines and Pyrimidines (RNY)(n) in gp120 of HIV Type1.
De Crignis E., Guglietta S., Foley B.T., Negroni M., Di Narzo A.F., Waelti Da Costa V., Cavassini M., Bart P.A., Pantaleo G., Graziosi C., 2012. Aids Research and Human Retroviruses, 28 (5) pp. 493-504.
 
NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients.
Harari A., Rozot V., Cavassini M., Enders F.B., Vigano S., Tapia G., Castro E., Burnet S., Lange J., Moog C. et al., 2012. European Journal of Immunology, 42 (11) pp. 3038-3048.
 
Patterns of Adherence to Raltegravir-Based Regimens and the Risk of Virological Failure Among HIV-Infected Patients: The RALTECAPS Cohort Study.
Gras G., Schneider M.P., Cavassini M., Lucht F., Loilier M., Verdon R., Bernard L., Parienti J.J., 2012. Journal of Acquired Immune Deficiency Syndromes, 61 (3) pp. 265-269.
 
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M., Fayet-Mello A., Lubomirov R., Neely M., di Iulio J., Owen A., Boffito M., Cavassini M., Günthard H.F., Rentsch K. et al., 2012. Antimicrobial Agents and Chemotherapy, 56 (6) pp. 2959-2966.
 
Pratiques de dépistage du VIH avant et après la révision des recommandations nationales dans un hôpital universitaire suisse
Kea. D. , Hugli O., Mamin R., Cellerai C., Martenet S., Berney A., Peters S., Du Pasquier R., Bodenmann P., Cavassini M., 2012. dans AFRAVIH 2012, Alliance Francophone des Acteurs de Santé contre le VIH/Sida.
 
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Young J., Schäfer J., Fux C.A., Furrer H., Bernasconi E., Vernazza P., Calmy A., Cavassini M., Weber R., Battegay M. et al., 2012. Aids, 26 (5) pp. 567-575.
 
Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study.
Bucher H.C., Richter W., Glass T.R., Magenta L., Wang Q., Cavassini M., Vernazza P., Hirschel B., Weber R., Furrer H. et al., 2012. Journal of Acquired Immune Deficiency Syndromes, 60 (2) pp. 135-142. Peer-reviewed.
 
Troubles de l'humeur et VIH: épidémiologie, clinique et prise en charge thérapeutique [Mood disorders in HIV patients: a challenge for liaison psychiatry consultation].
Maccaferri G.E., Cavassini M., Berney A., 2012. Revue Médicale Suisse, 8 (328) pp. 362-4, 366-7. Peer-reviewed.
Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes.
Fenner L., Gagneux S., Janssens J.P., Fehr J., Cavassini M., Hoffmann M., Bernasconi E., Schrenzel J., Bodmer T., Böttger E.C. et al., 2012. Plos One, 7 (3) pp. e34186.
Underreporting of needlestick and sharps injuries among healthcare workers in a Swiss University Hospital.
Voide C., Darling K.E., Kenfak-Foguena A., Erard V., Cavassini M., Lazor-Blanchet C., 2012. Swiss Medical Weekly, 142 (w13523) pp. 1-7.
Management of hepatitis C virus (HCV) infection in drug substitution programs.
Witteck A., Schmid P., Hensel-Koch K., Thurnheer M.C., Bruggmann P., Vernazza P., Swiss Hepatitis C and HIV Cohort Studies, 2011/05/27. Swiss medical weekly, 141 pp. w13193. Peer-reviewed.
Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.
di Iulio J., Ciuffi A., Fitzmaurice K., Kelleher D., Rotger M., Fellay J., Martinez R., Pulit S., Furrer H., Günthard H.F. et al., 2011/05. Hepatology, 53 (5) pp. 1446-1454. Peer-reviewed.
 
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
HIV-CAUSAL Collaboration, Cain L.E., Logan R., Robins J.M., Sterne J.A., Sabin C., Bansi L., Justice A., Goulet J., van Sighem A. et al., 2011/04/19. Annals of internal medicine, 154 (8) pp. 509-515. Peer-reviewed.
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University